186668-55-3

Basic information

• Product Name: 7-CHLORO-2,3-DIHYDRO-[1,4]DIOXINO[2,3-G]QUINOLINE-8-CARBALDEHYDE
• Synonyms: 7-CHLORO-2,3-DIHYDRO-[1,4]DIOXINO[2,3-G]QUINOLINE-8-CARBALDEHYDE;AKOS BBS-00005356
• CAS NO: 186668-55-3
• Molecular Formula: C12H8ClNO3
• Molecular Weight: 249.65
• Mol File: 186668-55-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7-CHLORO-2,3-DIHYDRO-[1,4]DIOXINO[2,3-G]QUINOLINE-8-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-CHLORO-2,3-DIHYDRO-[1,4]DIOXINO[2,3-G]QUINOLINE-8-CARBALDEHYDE(186668-55-3)
• EPA Substance Registry System: 7-CHLORO-2,3-DIHYDRO-[1,4]DIOXINO[2,3-G]QUINOLINE-8-CARBALDEHYDE(186668-55-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 186668-55-3(Hazardous Substances Data)

Upstream product

• 63546-19-0 N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acetamide 
• 68-12-2 N,N-dimethyl-formamide 
• 12591-02-5 phosphoryl oxychloride on N,N-dimethylformamide 
• 22013-33-8 6-amino-3,4-benzodioxane 

Downstream Products

• 1591639-27-8 3-amino-thieno[2,3-b]quinoline-2-carboxyamide 

Relevant articles and documents

NOVEL INHIBITORS OF PROTEIN KINASE C EPSILON SIGNALING

The present invention relates to novel inhibitors of protein kinase C epsilon (PKCε) signaling, including in particular the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these inhibitors, and their use in

HCV INHIBITORS AND METHODS OF USING THEM

The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and composit

Synthesis of novel 2,3-dihydro-1,4-dioxino[2,3-g]quinoline derivatives as potential antitumor agents

New dioxinoquinolines (1-8) have been synthesized and their antiproliferative properties have been tested against several cell lines. The treatment of the 6-acetamido-2,3-dihydro-1,4-benzodioxine (10) with phosphorous oxychloride in the presence of DMF le

Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them

A compound of the formula wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.

New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them

A compound of the formula wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.

Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues

The compound of the formula wherein the substituents are defined as in the specification and its non-toxic, pharmaceutically acceptable salts which are useful for the treatment of viral infections, parasitic diseases and the treatment of cancer.

Camptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues

A camptothecin analog characterized in that the hydroxy lactone of the camptothecin is a β-hydroxy lactone or the corresponding β-hydroxyacid, resulting from the opening of said lactone, or a derivative of said β-hydroxyacid, or a Pharmaceutically acceptable salt thereof, is disclosed. In particular, compounds of formulae (I) and (II) are disclosed. Methods for preparing the compounds of formulae (I) and (II), pharmaceutical compositions containing said containing said compounds, and their use, particularly as topoisomerase inhibitors and antitumoral drugs, are also disclosed.

Homocamptothecins: Synthesis and antitumor activity of novel E-ring- modified camptothecin analogues

Homocamptothecin (hCPT), a camptothecin (CPT) analogue with a seven membered β-hydroxylactone which combines enhanced plasma stability and potent topoisomerase I (Topo I) mediated activity, is an attractive template for the elaboration of new anticancer a